130 related articles for article (PubMed ID: 36976639)
21. Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
Queiroz MA; Viana P; Santos A; Bastos D; Etchebehere E; Cerri G
Clin Nucl Med; 2016 Sep; 41(9):e417-9. PubMed ID: 27276202
[TBL] [Abstract][Full Text] [Related]
22. Correlation between molecular tumor volume evaluated with
Medina-Ornelas Sevastián S; García-Pérez Francisco O; Hernández-Pedro Norma Y; Arellano-Zarate Angélica E; Abúndiz-López Blanca L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):223-228. PubMed ID: 29454548
[TBL] [Abstract][Full Text] [Related]
23. Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series.
Sollini M; Pasqualetti F; Perri M; Coraggio G; Castellucci P; Roncali M; Boni R; Lazzeri E; Galeandro M; Paiar F; Versari A; Erba PA
Cancer Imaging; 2016 Aug; 16(1):27. PubMed ID: 27581366
[TBL] [Abstract][Full Text] [Related]
24. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
McEwan LM; Wong D; Yaxley J
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
[TBL] [Abstract][Full Text] [Related]
25. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.
Damle NA; Bal C; Bandopadhyaya GP; Kumar L; Kumar P; Malhotra A; Lata S
Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765
[TBL] [Abstract][Full Text] [Related]
26. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
Moragas M; Soler M; Riera E; García JR
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
[TBL] [Abstract][Full Text] [Related]
27. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of prostate cancer using FDG-PET].
Kanamaru H; Oyama N; Akino H; Okada K
Hinyokika Kiyo; 2000 Nov; 46(11):851-3. PubMed ID: 11193311
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
30. Epiglottic Polymorphous Adenocarcinoma With Multiple Bone Metastases Detected by 68 Ga-FAPI PET/CT.
Pang Y; Meng T; Xu W; Kong L; Chen H
Clin Nucl Med; 2022 Nov; 47(11):1003-1006. PubMed ID: 35714373
[TBL] [Abstract][Full Text] [Related]
31. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Sadato N; Yonekura Y; Okada K
Jpn J Clin Oncol; 1999 Dec; 29(12):623-9. PubMed ID: 10721945
[TBL] [Abstract][Full Text] [Related]
32. The lytic skeletal lesions: A rare presentation of carcinoma prostate on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Pande S; Mhatre N; Dhal I
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S939-S942. PubMed ID: 38384085
[TBL] [Abstract][Full Text] [Related]
33. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy.
Shimizu N; Masuda H; Yamanaka H; Oriuchi N; Inoue T; Endo K
J Urol; 1999 Feb; 161(2):608-9. PubMed ID: 9915462
[No Abstract] [Full Text] [Related]
34. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
[TBL] [Abstract][Full Text] [Related]
35. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
37. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
38. The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.
Tabrizipour AI; Dunne M
Clin Nucl Med; 2015 May; 40(5):e285-6. PubMed ID: 25608148
[TBL] [Abstract][Full Text] [Related]
39. Widespread metastases in small cell carcinoma of the prostate on FDG PET/CT.
Yilmaz M; Celen Z; Sevinc A; Karakok M
Clin Nucl Med; 2009 Sep; 34(9):598-600. PubMed ID: 19692822
[TBL] [Abstract][Full Text] [Related]
40. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
